Rapalogues for Autism Phenotype in TSC: A Feasibility Study
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2016
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Pervasive child development disorders; Tuberous sclerosis
- Focus Therapeutic Use
- Acronyms RAPT
- 31 Aug 2018 Biomarkers information updated
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.